Tscan Therapeutics Inc
TCRX
Get informed when a big investor buys or sells
+ FollowMarket Cap$19.05M
Close$
$-1.58
533.6% downside
Current Fair Value
533.6% downsideOvervalued by 533.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $19.05 Million |
|---|---|
| Enterprise Value | $10.37 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1 |
| Beta | 1.07 |
| Outstanding Shares | 129,948,878 |
Return
| Return on Equity | -170.55% |
|---|---|
| Return on Assets | -68.66% |
| Return on Invested Capital | -84.76% |
Valuation & Multiples
| P/E Ratio | -0.34 |
|---|---|
| PEG | 1.92 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 2.25 |
| Enterprise Value to EBIT | -0.09 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 8.82 |
| Debt to Equity | 1.33 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 19, 2026
EPS Estimate
$-0.26
Average shareholder expectationRevenue Estimate
$1.88 M
Average shareholder expectationNext Earnings Call
Expected Date
November 11, 2026
EPS Estimate
$-0.26
Average shareholder expectationRevenue Estimate
$459,000
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 27.58%▲ 2.58% |
|---|---|
| Total Invested | $35.12M▲ 7.13% |
| Investors Holding | 59▲ 1.00% |
ESG Score
No data
About Tscan Therapeutics Inc
61 employees